Dominant-Negative TNFα AAV Gene Therapy for Localized Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-TNF agents for treating inflammatory and neurological conditions suffer from undesirable side effects, high costs, and limited efficacy due to systemic distribution, necessitating improved therapeutics that selectively target tissues and provide sustained delivery.
Innovation Solution
Adeno-associated virus (AAV) constructs encoding dominant-negative tumor necrosis factor alpha (DN-TNFα) polypeptides, linked to heterologous signal sequences, for targeted expression in specific tissues such as the brain, muscle, and eye, reducing inflammation and disease symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF agents are administered systemically to treat inflammatory and neurological conditions, then therapeutic efficacy is achieved, but undesirable side effects and serious complications occur
Solution Approach 1:
The patent employs AAV vectors with tissue-specific promoters (e.g., GFAP promoter for astrocytes, CamKII promoter for neurons) to achieve localized expression of DN-TNFα only in specific brain regions or cell types. This localised expression strategy maintains therapeutic efficacy in target tissues while minimizing systemic exposure and associated side effects such as opportunistic infections and malignancy risks
Solution Approach 2:
The patent uses adeno-associated virus (AAV) vectors as intermediary delivery systems to transport the DN-TNFα gene to specific target tissues. The AAV vector acts as a mediator that enables controlled, localized gene expression through its ability to transduce specific cell types in the brain and other tissues, thereby achieving therapeutic effects without requiring systemic administration of anti-TNF agents
2Reliability
If recombinant protein DN-TNFα is administered via continual injections to achieve therapeutic effect, then efficacy in inflammatory conditions is improved, but treatment durability and patient compliance deteriorate
Solution Approach 1:
The patent employs gene therapy approach where the DN-TNFα gene is delivered via AAV vector and integrated into the host genome or maintained as an episome. This preliminary genetic modification enables the host cells to produce DN-TNFα autonomously over extended periods, eliminating the need for continual protein injections and providing sustained therapeutic effect for months to years
Solution Approach 2:
The patent creates a self-sustaining therapeutic system where the delivered gene therapy construct enables target cells to continuously produce the therapeutic DN-TNFα protein. The transduced cells become self-service factories that autonomously synthesize and secrete DN-TNFα, maintaining therapeutic levels without requiring external re-administration of the protein
3Adaptability or versatility
If anti-TNF therapy is applied broadly to treat various inflammatory conditions, then patient coverage is improved, but cost and treatment complexity increase
Solution Approach 1:
The patent develops a universal AAV-based gene therapy platform that can treat multiple inflammatory and neurological conditions (Alzheimer's disease, Parkinson's disease, multiple sclerosis, rheumatoid arthritis, uveitis) using the same DN-TNFα construct. The versatility is achieved by selecting different AAV serotypes with varying tropisms and using tissue-specific promoters to adapt the same core therapy to different indications, thereby simplifying the overall treatment approach across diverse patient populations
Data Source
AI summary
The present disclosure provides AAV vector constructs that encode and deliver DN-TNFα polypeptides, compositions comprising the same and methods of their use in treating inflammatory conditions, such as neuroinflammatory conditions, systemic and peripheral inflammatory conditions, and ocular conditions. This disclosure also provides methods of making the AAV vector constructs that encode and deliver DN-TNFα polypeptides.